Abstract PO2-19-10: CAPItello-292 Phase 3: an Open-Label, Randomized Study of Capivasertib, Fulvestrant, and Investigator’s Choice of CDK4/6 Inhibitor (palbociclib or Ribociclib) in HR+/HER2– Advanced Breast Cancer
Cancer Research（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要